Unlike other treatments, immune checkpoint inhibitors (ICIs) are monoclonal antibodies designed to block negative regulators of T-cell function, including programmed death-1 (PD-1), PD-ligand 1 (PD-L1) and cytotoxic T lymphocyte antigen 4 (CTLA-4), etc, to activate anti-tumor immunity (1). This evidence concerns the gene CD274 and neoplasm.